30 closest matches · ranked by relevance
Glioblastoma · Gliosarcoma
Primary: Feasibility as Assessed by Successful Co-registration of sMRI-based Treatment Volumes With Clinical Images Into the Radiation Treatment Execution Platform — 30…
Brain and Central Nervous System Tumors
Primary: Median Overall Survival Time — 16.6; 14.9 months — p=0.63
Brain and Central Nervous System Tumors
Primary: Overall Survival After Treatment — 15.8; 22; 18.7; 12.5 months
High Grade Glioma
Primary: Response Rate
Glioblastoma · Gliosarcoma
Primary: Overall Survival (OS) — 19.8 months
Brain and Central Nervous System Tumors
Primary: Overall Survival — 19.1 months
Adult Anaplastic Astrocytoma · Adult Anaplastic Ependymoma · Adult Anaplastic Oligodendroglioma
Primary: Maximum Tolerated Dose (MTD) of Alisertib — 50 mg dose of Alisertib
High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma
Primary: ORR — 0; 0; 0; 0 percentage of patients
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Number of Patients Achieving 6-month Progression-free Survival (6mPFS) — 1; 2 participants
Malignant Glioma
Primary: Six-month Progression-free Survival (PFS6) — 14.3; 5; 14.3; 40 percentage of participants
Glioma
Primary: Progression Free Survival (PFS) Rate at Month 6 — 11.0; 21.2; 8.0; 7.6 Percentage of participants
Malignant Glioma
Primary: Number of Participants With Objective Radiographic Response — 5; 2 Participants
Adult Glioblastoma · Adult Gliosarcoma · Recurrent Adult Brain Neoplasm
Primary: Count/Percentage of Patients Progression-free at 6 Months for Bevacizumab and Irinotecan Hydrochloride Arm — 22 Participants
Brain and Central Nervous System Tumors
Primary: Overall Survival — 19.6; 21.1 Months
Glioblastoma
Primary: Safety, Tolerability, and Feasibility of Combination Intra-operative 5-ALA and Gliadel Wafers Prior to Adjuvant Radiotherapy Plus Temozolomide — 62; 9; 6; 45 Participants
Glioma
Primary: Number of Participants With the Indicated Change From Baseline to Study Completion in Systolic Blood Pressure — 21; 12; 11; 12 participants
Recurrent or Progressive Glioblastoma
Primary: Local Tumor Control — 14; 4 Participants
Glioblastoma · Gliosarcoma
Primary: Response Rate — 24.4 percentage of patients
Brain and Central Nervous System Tumors
Primary: (Phase III) Overall Survival (OS) — 3.9; 3.8 years — p=0.36
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Maximum Tolerated Dose (MTD) of the Each Combination Agent Combined With a Fixed Dose of BAY 43-9006 Determined by Dose-limiting Toxicities (DLT) (Phase I) — 100; 25; NA…
Glioblastoma Multiforme
Primary: Progression-free Survival — 6 Months
Glioma · Anaplastic Astrocytoma · Anaplastic Oligodendroglioma
Primary: Percentage of Dose-limiting Toxicities — 0; 0; 17 Percentage of dose-limiting toxicities
Adult Glioblastoma · Adult Gliosarcoma · Recurrent Adult Brain Neoplasm
Primary: Progression-free Survival — 17.1; 9.7 Proportion of Successes
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Maximum Tolerated Dose of MGd (Phase I) — 0; 0; 1 units on a scale
Adult Anaplastic Astrocytoma · Adult Diffuse Astrocytoma · Adult Giant Cell Glioblastoma
Primary: Progression-free Survival at 6 Months (Stratum 1) — 1 patients
Brain and Central Nervous System Tumors
Primary: Overall Survival Rate at 3 Years — 73.1 percentage of participants — p=<0.001
Recurrent Glioblastoma
Primary: Progression Free Survival (PFS) — 34.5 percentage of participants
Brain Tumor · Glioblastoma · Anaplastic Glioma
Primary: Maximum Tolerated Dose of Everolimus for Participants With Recurrent Malignant Gliomas — 5 mg
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: 6 Months Progression-free Survival — 3 percent
Recurrent Central Nervous System Neoplasm
Primary: 6 Month Progression-free Survival — 10; 50 percentage of patients